Lab Directors Look For Ways To Adjust To Proposed LDT Framework
This article was originally published in The Gray Sheet
Executive Summary
While many in the laboratory community protested loudly against FDA's plans to regulate lab-developed tests at a recent workshop, some tried to look ahead to how they could smoothly adjust to a dual regulatory system in which labs are regulated by CMS, while tests are approved by FDA.
You may also be interested in...
US Spending Bill Rider Looks To Stop Already Halted FDA LDT Guidance
A US FDA spending bill approved by the House Appropriations Committee July 12 would halt finalization of the agency's draft 2014 laboratory developed test guidance, recommending that FDA let Congress write its own bill directing any LDT regulation – but FDA already essentially handed the LDT reins to lawmakers last January.
Clinical Labs Lawyer Up In Battle Over LDTs
ACLA has recruited Laurence Tribe and Paul Clement, two prominent constitutional legal guns with Supreme Court expertise, to fight FDA over its proposed lab-developed test guidance. The announcement is perhaps the lab industry's most high profile move yet to oppose FDA's plan to regulate lab-developed test services under the device statute with a risk-based phase-in plan.
FDA Releases LDT Regulatory Framework, Notification Draft Guidances
Two promised draft guidances on FDA’s framework for regulating laboratory developed tests and notification and medical device reporting requirements for LDTs have been posted. The agency wants swift notification from labs for most available LDTs once a framework is finalized.